Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Purchased by ORG Partners LLC

ORG Partners LLC lifted its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 14,497.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,839 shares of the medical equipment provider's stock after buying an additional 5,799 shares during the period. ORG Partners LLC's holdings in Zimmer Biomet were worth $617,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the stock. BLB&B Advisors LLC lifted its position in Zimmer Biomet by 2.1% during the 3rd quarter. BLB&B Advisors LLC now owns 4,900 shares of the medical equipment provider's stock worth $529,000 after acquiring an additional 100 shares during the period. FWG Holdings LLC raised its stake in shares of Zimmer Biomet by 2.9% in the third quarter. FWG Holdings LLC now owns 3,591 shares of the medical equipment provider's stock worth $372,000 after purchasing an additional 101 shares during the last quarter. Financial Advocates Investment Management lifted its holdings in shares of Zimmer Biomet by 3.5% during the third quarter. Financial Advocates Investment Management now owns 3,053 shares of the medical equipment provider's stock worth $330,000 after purchasing an additional 103 shares during the period. M&R Capital Management Inc. boosted its position in Zimmer Biomet by 14.1% in the third quarter. M&R Capital Management Inc. now owns 852 shares of the medical equipment provider's stock valued at $92,000 after buying an additional 105 shares during the last quarter. Finally, Mill Creek Capital Advisors LLC increased its holdings in Zimmer Biomet by 5.1% in the 2nd quarter. Mill Creek Capital Advisors LLC now owns 2,195 shares of the medical equipment provider's stock worth $238,000 after buying an additional 106 shares during the period. 88.89% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have recently commented on ZBH. Truist Financial upped their price objective on shares of Zimmer Biomet from $117.00 to $118.00 and gave the company a "hold" rating in a report on Wednesday, December 18th. Barclays lowered their price target on shares of Zimmer Biomet from $125.00 to $118.00 and set an "underweight" rating on the stock in a report on Thursday, December 12th. Raymond James reduced their price objective on Zimmer Biomet from $128.00 to $123.00 and set an "outperform" rating for the company in a research note on Monday, October 14th. Oppenheimer lowered their target price on Zimmer Biomet from $145.00 to $135.00 and set an "outperform" rating on the stock in a research note on Tuesday, October 15th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Zimmer Biomet in a research report on Thursday, October 31st. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, Zimmer Biomet currently has a consensus rating of "Hold" and an average target price of $123.33.

Zimmer Biomet Trading Up 2.9 %

NYSE ZBH traded up $2.93 on Friday, reaching $104.47. 2,709,275 shares of the company were exchanged, compared to its average volume of 1,769,996. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $100.67 and a fifty-two week high of $133.90. The stock has a market capitalization of $20.80 billion, a P/E ratio of 19.86, a price-to-earnings-growth ratio of 1.96 and a beta of 1.02. The business's fifty day moving average price is $108.03 and its 200 day moving average price is $108.02. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.74. The firm had revenue of $1.82 billion during the quarter, compared to analysts' expectations of $1.80 billion. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. Zimmer Biomet's revenue was up 4.1% compared to the same quarter last year. During the same period last year, the business earned $1.65 earnings per share. Analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Monday, December 30th will be given a $0.24 dividend. The ex-dividend date is Monday, December 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.92%. Zimmer Biomet's dividend payout ratio is currently 18.25%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.